Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags
FAQ
How many Immatics N.V. (IMTX) SEC filings are available on StockTitan?
StockTitan tracks 71 SEC filings for Immatics N.V. (IMTX), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Immatics N.V. (IMTX)?
The most recent SEC filing for Immatics N.V. (IMTX) was filed on November 20, 2026.